bullish
Hutchmed China Ltd (13.HK/HCM.US) - High Growth Is Expected from 2024 to 2026
360 Views12 Mar 2024 08:55
HUTCHMED will enter a period of accelerated growth in product revenue based on major catalysts in 2024 to 2026. Global sales of fruquintinib will be the main driving force. Breakeven is drawing near.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Mar.22)-TCM Injection Revive, China CXO Lag Behind in GLP-1, United Imaging24 Mar 2024
- Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?20 Mar 2024
- Important New Policy for China’s Innovative Drugs – The Game Rule Is About to Change Radically18 Mar 2024
- Hutchmed China Ltd (13.HK/HCM.US) - High Growth Is Expected from 2024 to 202612 Mar 2024
- BeiGene (6160.HK/BGNE.US/688235.CH) - Pain Points Behind the High Growth05 Mar 2024
- Hutchmed China Ltd (13.HK/HCM.US) - 2023 Results Preview and Catalysts in 202420 Feb 2024
- Hutchmed China Ltd (13.HK/HCM.US) 23H1 - This Company Is Becoming More Attractive07 Aug 2023
x